Carvedilol is associated with lower mortality than other nonselective beta-blockers in patients with cirrhosis
These findings support the use of carvedilol in patients with cirrhosis and clinically apparent portal hypertension, to decrease the risk of hepatic decompensation and improve survival.
Authors
- Michael F. Mullarkey
- Sumeet K. Asrani (ORCID: https://orcid.org/0000-0001-9174-5670)
- Michael L. Volk (ORCID: https://orcid.org/0000-0001-7069-0754)
- Gerald O. Ogola (ORCID: https://orcid.org/0000-0003-4934-9791)
Institutions
- Baylor University Medical Center (US)
- Baylor Medical Center at Garland (US)
- Baylor Scott & White Health (US)
Publication Details
- Journal
- Baylor University Medical Center Proceedings
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1080/08998280.2025.2491220
- Citations
- 2
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 2.64